MYRIAD GENETICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
MYRIAD GENETICS, INC. (MYGN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2025-02-28
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2017-06-30 was $0.00.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2017-03-31 was $0.00.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2016-12-31 was $0.00.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2016-09-30 was $130.00M.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2024 was $0.00.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2022 was $2.10M, a 16.67% increase from fiscal 2021.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2021 was $1.80M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-02-28 | -$1.50M 10-K · filed 2024-02-28 | |||
| 2022-12-31 | $2.10M 10-K · filed 2025-02-28 | ||||
| 2021-12-31 | $1.80M 10-K · filed 2024-02-28 | $0.00 10-K · filed 2023-03-01 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 | ||||
| 2020-06-30 | $0.00 10-K · filed 2023-03-01 | ||||
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-09 | $0.00 derived: sum of 2 quarters · filed 2017-08-09 | $0.00 derived: sum of 3 quarters · filed 2017-08-09 | $130.00M 10-K · filed 2017-08-09 | |
| 2017-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-03 | $0.00 derived: sum of 2 quarters · filed 2017-05-03 | $130.00M 10-Q · filed 2017-05-03 | ||
| 2016-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-08 | $130.00M 10-Q · filed 2017-02-08 | |||
| 2016-09-30 | $130.00M 10-Q · filed 2016-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |